TORONTO, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. (TSX-V:GES) (MUN:1GE) ("Gemoscan" or the "Company"), is pleased to announce that the HemocodeTM System and its other food sensitivity management programs are expected to be available in the United States in the third or fourth quarter of this 2014. Working with its exclusive laboratory partner, American Metabolic Testing Laboratories, Inc., ("AMTL"), Gemoscan has completed work on the laboratory protocols necessary to fulfill its diet and nutrition programs in the U.S; and has concluded an agreement with AMTL to do so.
The HemocodeTM System like the Company's other programs is a personalized medically supervised nutritional program that promotes dietary well being. It uses portions of Gemoscan's patented technology, and proprietary services to provide consultation and recommendations intended to simplify the management of food sensitivities. HemocodeTM is offered by over 600 pharmacies and medical clinics in Canada as a complementary medical choice. HemocodeTM and the Company's other food sensitivity management programs are used as adjuncts in conventional medical practices, incorporating complementary modalities and therapies with a focus on lifestyle and wellness. A statistically significant base of practitioners and those engaging with HemocodeTM have reported improved dietary and overall wellness satisfaction.
"Over the past year we have had the opportunity to work with American Metabolic Testing Laboratories, Inc., and its founder Dr. Emil Schandl to finalize our U.S laboratory protocols, and are now eager to make our unique food sensitivity and dietary wellness programs available throughout the United States," said Brian Kalish, CEO of Gemoscan.
American Metabolic Testing Laboratories, Inc., was founded in 1995 by Dr. Emil K. Schandl, PhD., M.Sc., and is accredited by CLIA (Clinical Laboratory Improvement Amendments of 1988) and COLA (the Commission on Office Laboratory Accreditation). AMTL provides the CA Profile™ (Cancer Profile) and Longevity Profile™ testing for doctors and patients throughout the United States and around the world including Asia, Europe, Africa, Australia and more.
In addition to a number of other certifications, and distinctions, Dr. Schandl is a Fellow at the National Academy of Clinical Biochemistry; a Specialist in Clinical Chemistry with the American Society of Clinical Pathologists; a Clinical Chemist with the National Registry in Clinical Chemistry, a Clinical Laboratory Director in: FL, NY and CA and is a past member of Sigma Xi Scientific Society of America.
"At American Metabolic Testing Laboratories, Inc., we are excited to be fulfilling the HemocodeTM System with Gemoscan. Hemocode's panels complement our existing tests, especially our CA Profile™ (Cancer Profile) and Longevity Profile™, as we understand that food sensitivity may be a contributing factor to the development of cancer in individuals," said Dr. E.K. Schandl, PhD., Laboratory Director at American Metabolic Testing Laboratories. Dr. Schandl continued "While we have been approached by a number of companies in the past for cooperation, Gemoscan is the first we have agreed to venture with; and we look forward to continuing to contribute to the health and welfare of our fellow citizens through a successful relationship in providing the HemocodeTM System with Gemoscan."
About Gemoscan Canada, Inc.
Gemoscan is an industry leader in food intolerance management and maintains a first-to-market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology, Gemoscan develops, owns and markets comprehensive naturopathic dietary management solutions for consumers, including the HemocodeTM System and the MenuWise™ Plan, personalized medically supervised programs that promote dietary well-being. Gemoscan is the first and only provider to commercialize a food sensitivity management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available. Gemoscan also owns and operates multidisciplinary paramedical clinics, located in Toronto, Ontario.
Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.
This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward- looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.